Cove Street Capital LLC Grows Stock Holdings in Avanos Medical, Inc. $AVNS

Cove Street Capital LLC lifted its holdings in Avanos Medical, Inc. (NYSE:AVNS) by 430.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 112,081 shares of the company’s stock after acquiring an additional 90,963 shares during the quarter. Avanos Medical accounts for 1.7% of Cove Street Capital LLC’s holdings, making the stock its 26th biggest position. Cove Street Capital LLC owned approximately 0.24% of Avanos Medical worth $1,296,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in AVNS. Armistice Capital LLC boosted its holdings in Avanos Medical by 1.8% in the second quarter. Armistice Capital LLC now owns 2,036,000 shares of the company’s stock valued at $24,921,000 after purchasing an additional 36,000 shares during the last quarter. Clark Estates Inc. NY raised its stake in shares of Avanos Medical by 58.7% during the 3rd quarter. Clark Estates Inc. NY now owns 783,880 shares of the company’s stock valued at $9,062,000 after buying an additional 290,000 shares during the last quarter. Qube Research & Technologies Ltd lifted its holdings in shares of Avanos Medical by 32.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 625,409 shares of the company’s stock valued at $7,655,000 after buying an additional 153,547 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Avanos Medical by 116.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 577,889 shares of the company’s stock valued at $6,680,000 after buying an additional 311,317 shares during the period. Finally, AQR Capital Management LLC boosted its stake in shares of Avanos Medical by 190.4% in the second quarter. AQR Capital Management LLC now owns 560,052 shares of the company’s stock worth $6,855,000 after buying an additional 367,188 shares during the last quarter. Hedge funds and other institutional investors own 95.17% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on AVNS. Wall Street Zen lowered Avanos Medical from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Avanos Medical in a research report on Monday, December 22nd. Finally, Zacks Research raised shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a research note on Monday, January 26th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Reduce”.

Avanos Medical Price Performance

NYSE:AVNS opened at $13.71 on Friday. Avanos Medical, Inc. has a 12 month low of $9.30 and a 12 month high of $15.68. The stock has a 50 day moving average of $13.49 and a two-hundred day moving average of $12.26. The company has a current ratio of 2.15, a quick ratio of 1.26 and a debt-to-equity ratio of 0.12. The firm has a market cap of $637.33 million, a P/E ratio of -8.67 and a beta of 1.07.

Avanos Medical (NYSE:AVNS) last released its earnings results on Tuesday, February 24th. The company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.05. The business had revenue of $180.90 million for the quarter, compared to the consensus estimate of $174.70 million. Avanos Medical had a positive return on equity of 5.47% and a negative net margin of 10.40%.The business’s quarterly revenue was up .7% compared to the same quarter last year. During the same quarter last year, the business posted $0.43 earnings per share. Avanos Medical has set its FY 2026 guidance at 0.900-1.100 EPS. On average, analysts expect that Avanos Medical, Inc. will post 1.32 earnings per share for the current fiscal year.

Avanos Medical Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.